EHA 2010

 
 
 

15th Congress of the European Hematology Association.

 

Patient advocacy in clinical trials

Jen Smith Read Article
Published: 07/12/10

 Andras Fehervary
Andras Fehervary

Though recent developments aim to improve the clinical trial process, a group of experts says much more work is necessary. At the 15th Congress of the European Hematology Association, three speakers discussed the patient-specific challenges of the clinical trial process and offered potential solutions to overcome them. The speakers attacked the issue from all sides, as each represented a different perspective: that of the clinician, the pharmaceutical industry, and the patient. [Read Article]

EZH2 in MPNs and MDS

Jen Smith Read Article
Published: 07/09/10

 Thomas Ernst, MD
Thomas Ernst, MD

New research indicates mutations of the histone methyltransferase EZH2 confer poor prognosis in myeloproliferative neoplasms (MPNs) and myelodysplastic syndrome (MDS), which suggests EZH2 acts as a tumor suppressor in myeloid malignancies. Thomas Ernst, MD, of Wessex Regional Genetics Laboratory in the United Kingdom, discussed the research that led to these conclusions at the Presidential Symposium of the 15th Congress of the European Hematology Association, which took place June 10-13 in Barcelona. [Read Article]

New drug active across subtypes of DLBCL

Jen Smith Read Article
Published: 07/08/10

 Allison Berger, PhD
Allison Berger, PhD

An investigational drug exhibits antitumor activity across multiple subtypes of diffuse large B-cell lymphoma (DLBCL) and is more active than bortezomib, according to a preclinical study. Past research indicated the second-generation proteasome inhibitor MLN9708 is effective against lymphoma. So researchers at Millennium Pharmaceuticals, Inc., the company that manufactures MLN9708, attempted to determine the drug’s efficacy in DLBCL. [Read Article]

New agent active in relapsed/refractory malignancies

Jen Smith Read Article
Published: 07/06/10

Brown.jpg
Jennifer Brown, MD, PhD

A PI3Kd inhibitor demonstrates considerable activity in certain relapsed or refractory hematologic malignancies. In a phase 1 study, CAL-101 was shown to be active and well tolerated in patients with indolent non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). Jennifer Brown, MD, PhD, of Dana-Farber Cancer Institute, and her fellow researchers administered CAL-101 to 106 patients with various relapsed or refractory diseases. [Read Article]

TKIs might hinder effects of allo-SCT in CML

Jen Smith Read Article
Published: 07/05/10

Inge Jedema, PhD
Inge Jedema, PhD

Researchers have discovered a subgroup of quiescent leukemic stem cells that are resistant to tyrosine kinase inhibitors (TKIs), alloreactive T cells, and natural killer (NK) cells. This finding indicates that TKIs do not act synergistically with immunological interventions, and the agents might actually hinder the immune response of allogeneic stem cell transplant. Inge Jedema, PhD, and her colleagues at Leiden University Medical Center in the Netherlands came to these conclusions after extensive study of CD34+ chronic myeloid leukemia (CML) cells. [Read Article]

PBI-1402: A safer ESA?

Jen Smith Read Article
Published: 06/29/10

Primera Technology, Inc.
©Primera Technology, Inc.

A novel erythropoiesis-stimulating agent (ESA) reduces the need for blood transfusions in chemotherapy-induced anemia (CIA) without conferring the dangerous side effects associated with other ESAs, according to a study presented at the 15th Congress of the European Hematology Association. A previous study showed that the ESA PBI-1402 increases relative and absolute reticulocyte counts in healthy volunteers without significant side effects. Preclinical research revealed PBI-1402 has antitumor activity, which suggests the drug is safe for patients who have anemia associated with cancer or resulting from chemotherapy. [Read Article]

MYC linked to survival in MM

Jen Smith Read Article
Published: 06/21/10

 Leif Bergsagel, MD
Leif Bergsagel, MD

MYC activation plays a key role in the prognosis of multiple myeloma (MM), according to an expert in the field. A speaker at the recent 15th Congress of the European Hematology Association cited a myriad of research indicating that MYC is important to the pathogenesis of MM. His latest research takes that finding a step further, suggesting that MYC activation is linked to survival in MM patients. [Read Article]

Team finds new target for AML therapy

Jen Smith Read Article
Published: 06/18/10

 Meritxell Alberich Jorda, PhD
Meritxell Alberich Jorda, PhD

Research presented at the 15th Congress of the European Hematology Association may provide a new therapeutic strategy for acute myeloid leukemia (AML). Meritxell Alberich Jorda, PhD, of Harvard Medical School, and her colleagues have discovered a link between CEBPG and CEBPA that suggests the former could be a promising target for AML therapy. [Read Article]

Rituximab maintenance: A new standard for FL?

Jen Smith Read Article
Published: 06/17/10

Gilles Salles, MD, PhD
Gilles Salles, MD, PhD

A new use for an old standby has proven successful enough that it may alter the standard treatment for follicular lymphoma (FL). Results of the PRIMA trial suggest that rituximab as 2-year maintenance therapy can reduce disease progression by 50% in FL patients who respond to an induction regimen of chemotherapy plus rituximab. Gilles Salles, MD, PhD, of Centre Hospitalier Lyon-Sud in France, and his colleagues initiated the PRIMA trial based on indications from previous studies that rituximab maintenance can prolong the efficacy of some induction regimens. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}